DaShenLin Pharmaceutical Group Co., Ltd. (SHA: 603233)

DaShenLin Pharmaceutical Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	5,708	4,416	4,493	2,792	3,750	1,716
Short-Term Investments	-	-	-	-	-	903.8
Trading Asset Securities	15.85	41.99	91.99	109.37	689.98	-
Cash & Short-Term Investments	5,724	4,458	4,585	2,902	4,440	2,620
Cash Growth	53.05%	-2.76%	58.01%	-34.65%	69.49%	97.13%
Accounts Receivable	1,231	1,234	1,022	743.82	432.32	355.69
Other Receivables	449.86	436.53	368.24	308.18	226.97	219.82
Receivables	1,681	1,671	1,390	1,052	659.29	575.52
Inventory	4,207	4,181	3,872	3,630	2,683	2,055
Prepaid Expenses	-	11.97	39.03	43.79	-	111.66
Other Current Assets	458.11	476.21	783.06	240.19	515.14	105.91
Total Current Assets	12,070	10,798	10,670	7,868	8,297	5,468
Property, Plant & Equipment	7,212	7,301	6,095	5,654	1,287	1,119
Long-Term Investments	155.59	155.59	132.16	150.17	150.3	116.95
Goodwill	3,555	3,024	2,364	2,060	1,334	983.73
Other Intangible Assets	1,953	1,859	637.19	618.8	489.98	351.93
Long-Term Deferred Tax Assets	211.83	214.48	186.31	157.57	41.53	38.38
Long-Term Deferred Charges	690.42	670.03	663.03	669.76	571.86	491.73
Other Long-Term Assets	31.31	101.12	94.19	157.99	160.02	102.04
Total Assets	25,879	24,123	20,841	17,336	12,332	8,672
Accounts Payable	8,114	6,871	6,127	4,738	4,215	3,200
Accrued Expenses	271.41	757.54	809.87	488.83	449.34	342.73
Short-Term Debt	1,555	744.89	697.31	165.44	190.86	63.47
Current Portion of Long-Term Debt	1,192	14.84	7.64	-	1.04	5.37
Current Portion of Leases	-	1,041	974.67	905.59	-	-
Current Income Taxes Payable	247.16	176.21	138.41	98.67	135.51	68.81
Current Unearned Revenue	380.56	362.4	435.73	164.11	68.11	44.91
Other Current Liabilities	1,391	1,486	516.59	615.14	408.79	277.94
Total Current Liabilities	13,150	11,454	9,708	7,176	5,468	4,003
Long-Term Debt	1,790	1,638	1,461	1,252	1,207	260.45
Long-Term Leases	2,787	3,070	2,790	2,952	-	-
Long-Term Unearned Revenue	17.06	19.3	17.64	20.12	83.27	76.94
Other Long-Term Liabilities	9.75	9.67	0.33	-	-	-
Total Liabilities	17,754	16,190	13,977	11,400	6,759	4,340
Common Stock	1,139	1,139	949.12	790.93	658.62	539.54
Additional Paid-In Capital	1,318	1,355	1,537	1,643	1,762	1,515
Retained Earnings	4,324	4,170	3,573	2,933	2,874	2,140
Treasury Stock	-100.72	-29.72	-36.68	-77.59	-99.41	-
Comprehensive Income & Other	189.92	189.94	189.94	189.96	189.97	45.71
Total Common Equity	6,870	6,824	6,212	5,479	5,385	4,240
Minority Interest	1,255	1,109	652.27	457.3	188.09	91.8
Shareholders' Equity	8,125	7,933	6,864	5,936	5,573	4,332
Total Liabilities & Equity	25,879	24,123	20,841	17,336	12,332	8,672
Total Debt	7,324	6,508	5,931	5,275	1,399	329.29
Net Cash (Debt)	-1,600	-2,050	-1,346	-2,373	3,041	2,291
Net Cash Growth	-	-	-	-	32.77%	134.65%
Net Cash Per Share	-1.41	-1.81	-1.18	-2.10	2.68	2.08
Filing Date Shares Outstanding	1,139	1,139	1,139	1,139	1,138	1,119
Total Common Shares Outstanding	1,139	1,139	1,139	1,139	1,138	1,119
Working Capital	-1,080	-655.27	962.03	692.26	2,829	1,465
Book Value Per Share	6.03	5.99	5.45	4.81	4.73	3.79
Tangible Book Value	1,362	1,941	3,211	2,800	3,561	2,904
Tangible Book Value Per Share	1.20	1.70	2.82	2.46	3.13	2.60
Buildings	-	2,016	1,076	800.43	775.04	625.88
Machinery	-	1,460	1,257	1,119	938.4	758.63
Construction In Progress	-	874.53	1,049	765.67	170.91	181.62

Source: S&P Capital IQ. Standard template. Financial Sources.